Europe Gene Fusion Testing Market: Analysis and Forecast, 2023-2033
This report will be delivered in 1-5 working days.
Introduction to Europe Gene Fusion Testing Market
The Europe gene fusion testing market was valued at $71.4 million in 2023 and is anticipated to reach $248.2 million by 2033, witnessing a CAGR of 13.27% during the forecast period 2023-2033. The gene fusion testing market is anticipated to experience growth due to the increasing use of gene fusion testing for the advancement of targeted therapies.
Market Introduction
The gene fusion testing market in Europe is experiencing significant growth and evolution. This can be attributed to several factors, including the region's increasing focus on precision medicine and the development of targeted therapies. Gene fusion testing, which involves identifying genetic alterations that drive certain diseases, plays a pivotal role in tailoring treatments to individual patients. Europe's commitment to healthcare innovation and research is fostering advancements in gene fusion testing technologies, making them more accessible and accurate. Additionally, the region's strong pharmaceutical and biotechnology sectors are driving demand for these tests as they seek to develop novel therapeutics.
Furthermore, regulatory support and collaborations between research institutions and industry players are contributing to market expansion. As Europe continues to emphasize personalized medicine and molecular diagnostics, the gene fusion testing market in the region is poised for continued growth and innovation.
Market Segmentation:
Segmentation 1: by Indication
Workflow/Innovation Strategy: The Europe gene fusion testing market (by indication) has been segmented into solid tumors and hematological malignancies. Moreover, the study provides the reader with a detailed understanding of the different indication of gene fusion testing in solid tumors.
Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic method employed to identify and analyze distinct genetic alterations in cancer cells. It arises when two distinct genes, typically from different chromosomes, abnormally join together, giving rise to a hybrid gene that generates a unique protein with modified functions.
Competitive Strategy: Key players in the Europe gene fusion testing market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe gene fusion testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
Introduction to Europe Gene Fusion Testing Market
The Europe gene fusion testing market was valued at $71.4 million in 2023 and is anticipated to reach $248.2 million by 2033, witnessing a CAGR of 13.27% during the forecast period 2023-2033. The gene fusion testing market is anticipated to experience growth due to the increasing use of gene fusion testing for the advancement of targeted therapies.
Market Introduction
The gene fusion testing market in Europe is experiencing significant growth and evolution. This can be attributed to several factors, including the region's increasing focus on precision medicine and the development of targeted therapies. Gene fusion testing, which involves identifying genetic alterations that drive certain diseases, plays a pivotal role in tailoring treatments to individual patients. Europe's commitment to healthcare innovation and research is fostering advancements in gene fusion testing technologies, making them more accessible and accurate. Additionally, the region's strong pharmaceutical and biotechnology sectors are driving demand for these tests as they seek to develop novel therapeutics.
Furthermore, regulatory support and collaborations between research institutions and industry players are contributing to market expansion. As Europe continues to emphasize personalized medicine and molecular diagnostics, the gene fusion testing market in the region is poised for continued growth and innovation.
Market Segmentation:
Segmentation 1: by Indication
- Solid Tumors
- Hematological Malignancies
- U.K.
- Germany
- France
- Spain
- Italy
- Netherlands
- Rest-of-Europe
Workflow/Innovation Strategy: The Europe gene fusion testing market (by indication) has been segmented into solid tumors and hematological malignancies. Moreover, the study provides the reader with a detailed understanding of the different indication of gene fusion testing in solid tumors.
Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic method employed to identify and analyze distinct genetic alterations in cancer cells. It arises when two distinct genes, typically from different chromosomes, abnormally join together, giving rise to a hybrid gene that generates a unique protein with modified functions.
Competitive Strategy: Key players in the Europe gene fusion testing market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe gene fusion testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
- Biocartis
- F. Hoffmann-La Roche Ltd
- OncoDNA
- QIAGEN N.V
Executive Summary
1 MARKET SCOPE
1.1 Key Questions Answered in the Report
2 RESEARCH METHODOLOGY
3 MARKET OVERVIEW
3.1 Introduction to Gene Fusion Testing
3.1.1 Different Technologies for Gene Fusion Testing
3.1.2 Advantages and Limitations of Gene Fusion Testing
3.1.3 Current Market Size and Future Growth Potential, $Million, 2022-2033
3.1.3.1 Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion vs. Other Gene Fusions
3.1.4 Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
3.1.5 Reimbursement Landscape
3.2 Stakeholder’s Survey Response
3.2.1 Awareness of Gene Fusion Testing
3.2.2 Familiarity with the NGS Offerings of the Following Companies
3.2.3 Adoption and Barriers for Gene Fusion Testing
4 INDUSTRY OUTLOOK
4.1 Regulatory Landscape
4.1.1 Legal Requirements and Frameworks in Europe
5 GENE FUSION TESTING MARKET (BY REGION), VALUE ($MILLION), 2022-2033
5.1 Overview
5.2 Europe
5.2.1 Europe Gene Fusion Testing Market, by Indication
5.2.2 Europe Gene Fusion Testing Market (by Country)
5.2.2.1 Germany
5.2.2.1.1 Germany Gene Fusion Testing Market (by Indication)
5.2.2.2 France
5.2.2.2.1 France Gene Fusion Testing Market (by Indication)
5.2.2.3 U.K.
5.2.2.3.1 U.K. Gene Fusion Testing Market (by Indication)
5.2.2.4 Italy
5.2.2.4.1 Italy Gene Fusion Testing Market (by Indication)
5.2.2.5 Spain
5.2.2.5.1 Spain Gene Fusion Testing Market (by Indication)
5.2.2.6 Netherlands
5.2.2.6.1 Netherlands Gene Fusion Testing Market (by Indication)
5.2.2.7 Rest-of-Europe
5.2.2.7.1 Rest-of-Europe Gene Fusion Testing Market (by Indication)
6 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
6.1 Overview
6.2 Biocartis
6.2.1 Company Overview
6.2.2 Role of Biocartis in the Gene Fusion Testing Market
6.2.3 Key Competitors
6.2.4 Recent Developments
6.2.5 Financials
6.2.6 Key Insights about the Financial Health of the Company
6.2.7 Analyst Perspective
6.3 F. Hoffmann-La Roche Ltd
6.3.1 Company Overview
6.3.2 Role of F. Hoffmann-La Roche Ltd in the Gene Fusion Testing Market
6.3.3 Key Competitors
6.3.4 Recent Developments
6.3.5 Financials
6.3.6 Key Insights about the Financial Health of the Company
6.3.7 Analyst Perspective
6.4 OncoDNA
6.4.1 Company Overview
6.4.2 Role of OncoDNA in the Gene Fusion Testing Market
6.4.3 Key Competitors
6.4.4 Recent Developments
6.4.5 Analyst Perspective
6.5 QIAGEN N.V.
6.5.1 Company Overview
6.5.2 Role of QIAGEN N.V. in the Gene Fusion Testing Market
6.5.3 Key Competitors
6.5.4 Recent Developments
6.5.5 Financials
6.5.6 Key Insights about the Financial Health of the Company
6.5.7 Analyst Perspective
List of Figures
Figure 1: Europe Gene Fusion Testing Market, $Million, 2022-2033
Figure 2: Europe Gene Fusion Testing Market: Drivers, Restraints, and Opportunities
Figure 3: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 4: Europe Gene Fusion Testing Market: Research Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: Different Approaches to Study Gene Fusion
Figure 9: Different Techniques Used in Gene Fusion Testing
Figure 10: Europe Gene Fusion Testing Market, $Million, 2022-2033
Figure 11: Artificial Intelligence and Machine Learning in Gene Fusion Testing
Figure 12: SOPHiA DDM RNAtarget Technology Workflow
Figure 13: Awareness to the Concept of Gene Fusion Testing
Figure 14: Familarity with NGS Offerings by Key Market Players for Gene Fusion Testing
Figure 15: Perceived Importance of Key Drivers to Improve Gene Fusion Testing Adoption
Figure 16: Agreement Level with Key Barriers to Gene Fusion Testing Adoption
Figure 17: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
Figure 18: Gene Fusion Testing Market (by Region), $Million, 2022 and 2033
Figure 19: Europe Gene Fusion Testing Market, $Million, 2022-2033
Figure 20: Europe: Market Dynamics
Figure 21: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 22: Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 23: Germany Gene Fusion Testing Market, $Million, 2022-2033
Figure 24: Germany Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 25: Germany Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 26: France Gene Fusion Testing Market, $Million, 2022-2033
Figure 27: France Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 28: France Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 29: U.K. Gene Fusion Testing Market, $Million, 2022-2033
Figure 30: U.K. Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 31: U.K. Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 32: Italy Gene Fusion Testing Market, $Million, 2022-2033
Figure 33: Italy Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 34: Italy Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 35: Spain Gene Fusion Testing Market, $Million, 2022-2033
Figure 36: Spain Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 37: Spain Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 38: Netherlands Gene Fusion Testing Market, $Million, 2022-2033
Figure 39: Netherlands Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 40: Netherlands Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 41: Rest-of-Europe Gene Fusion Testing Market, $Million, 2022-2033
Figure 42: Rest-of-Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 43: Rest-of-Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 44: Gene Fusion Testing Market (by Total Number of Companies Profiled)
Figure 45: Biocartis: Product Portfolio
Figure 46: Biocartis: Overall Financials, $Million, 2020-2022
Figure 47: Biocartis: Revenue (by Segment), $Million, 2020-2022
Figure 48: Biocartis: Revenue (by Region), $Million, 2020-2022
Figure 49: Biocartis: R&D Expenditure, $Million, 2020-2022
Figure 50: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 51: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 52: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 53: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 54: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 55: OncoDNA: Product Portfolio
Figure 56: QIAGEN N.V.: Product Portfolio
Figure 57: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 58: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 59: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 60: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
1 MARKET SCOPE
1.1 Key Questions Answered in the Report
2 RESEARCH METHODOLOGY
3 MARKET OVERVIEW
3.1 Introduction to Gene Fusion Testing
3.1.1 Different Technologies for Gene Fusion Testing
3.1.2 Advantages and Limitations of Gene Fusion Testing
3.1.3 Current Market Size and Future Growth Potential, $Million, 2022-2033
3.1.3.1 Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion vs. Other Gene Fusions
3.1.4 Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
3.1.5 Reimbursement Landscape
3.2 Stakeholder’s Survey Response
3.2.1 Awareness of Gene Fusion Testing
3.2.2 Familiarity with the NGS Offerings of the Following Companies
3.2.3 Adoption and Barriers for Gene Fusion Testing
4 INDUSTRY OUTLOOK
4.1 Regulatory Landscape
4.1.1 Legal Requirements and Frameworks in Europe
5 GENE FUSION TESTING MARKET (BY REGION), VALUE ($MILLION), 2022-2033
5.1 Overview
5.2 Europe
5.2.1 Europe Gene Fusion Testing Market, by Indication
5.2.2 Europe Gene Fusion Testing Market (by Country)
5.2.2.1 Germany
5.2.2.1.1 Germany Gene Fusion Testing Market (by Indication)
5.2.2.2 France
5.2.2.2.1 France Gene Fusion Testing Market (by Indication)
5.2.2.3 U.K.
5.2.2.3.1 U.K. Gene Fusion Testing Market (by Indication)
5.2.2.4 Italy
5.2.2.4.1 Italy Gene Fusion Testing Market (by Indication)
5.2.2.5 Spain
5.2.2.5.1 Spain Gene Fusion Testing Market (by Indication)
5.2.2.6 Netherlands
5.2.2.6.1 Netherlands Gene Fusion Testing Market (by Indication)
5.2.2.7 Rest-of-Europe
5.2.2.7.1 Rest-of-Europe Gene Fusion Testing Market (by Indication)
6 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
6.1 Overview
6.2 Biocartis
6.2.1 Company Overview
6.2.2 Role of Biocartis in the Gene Fusion Testing Market
6.2.3 Key Competitors
6.2.4 Recent Developments
6.2.5 Financials
6.2.6 Key Insights about the Financial Health of the Company
6.2.7 Analyst Perspective
6.3 F. Hoffmann-La Roche Ltd
6.3.1 Company Overview
6.3.2 Role of F. Hoffmann-La Roche Ltd in the Gene Fusion Testing Market
6.3.3 Key Competitors
6.3.4 Recent Developments
6.3.5 Financials
6.3.6 Key Insights about the Financial Health of the Company
6.3.7 Analyst Perspective
6.4 OncoDNA
6.4.1 Company Overview
6.4.2 Role of OncoDNA in the Gene Fusion Testing Market
6.4.3 Key Competitors
6.4.4 Recent Developments
6.4.5 Analyst Perspective
6.5 QIAGEN N.V.
6.5.1 Company Overview
6.5.2 Role of QIAGEN N.V. in the Gene Fusion Testing Market
6.5.3 Key Competitors
6.5.4 Recent Developments
6.5.5 Financials
6.5.6 Key Insights about the Financial Health of the Company
6.5.7 Analyst Perspective
List of Figures
Figure 1: Europe Gene Fusion Testing Market, $Million, 2022-2033
Figure 2: Europe Gene Fusion Testing Market: Drivers, Restraints, and Opportunities
Figure 3: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 4: Europe Gene Fusion Testing Market: Research Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: Different Approaches to Study Gene Fusion
Figure 9: Different Techniques Used in Gene Fusion Testing
Figure 10: Europe Gene Fusion Testing Market, $Million, 2022-2033
Figure 11: Artificial Intelligence and Machine Learning in Gene Fusion Testing
Figure 12: SOPHiA DDM RNAtarget Technology Workflow
Figure 13: Awareness to the Concept of Gene Fusion Testing
Figure 14: Familarity with NGS Offerings by Key Market Players for Gene Fusion Testing
Figure 15: Perceived Importance of Key Drivers to Improve Gene Fusion Testing Adoption
Figure 16: Agreement Level with Key Barriers to Gene Fusion Testing Adoption
Figure 17: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
Figure 18: Gene Fusion Testing Market (by Region), $Million, 2022 and 2033
Figure 19: Europe Gene Fusion Testing Market, $Million, 2022-2033
Figure 20: Europe: Market Dynamics
Figure 21: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 22: Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 23: Germany Gene Fusion Testing Market, $Million, 2022-2033
Figure 24: Germany Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 25: Germany Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 26: France Gene Fusion Testing Market, $Million, 2022-2033
Figure 27: France Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 28: France Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 29: U.K. Gene Fusion Testing Market, $Million, 2022-2033
Figure 30: U.K. Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 31: U.K. Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 32: Italy Gene Fusion Testing Market, $Million, 2022-2033
Figure 33: Italy Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 34: Italy Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 35: Spain Gene Fusion Testing Market, $Million, 2022-2033
Figure 36: Spain Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 37: Spain Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 38: Netherlands Gene Fusion Testing Market, $Million, 2022-2033
Figure 39: Netherlands Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 40: Netherlands Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 41: Rest-of-Europe Gene Fusion Testing Market, $Million, 2022-2033
Figure 42: Rest-of-Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
Figure 43: Rest-of-Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
Figure 44: Gene Fusion Testing Market (by Total Number of Companies Profiled)
Figure 45: Biocartis: Product Portfolio
Figure 46: Biocartis: Overall Financials, $Million, 2020-2022
Figure 47: Biocartis: Revenue (by Segment), $Million, 2020-2022
Figure 48: Biocartis: Revenue (by Region), $Million, 2020-2022
Figure 49: Biocartis: R&D Expenditure, $Million, 2020-2022
Figure 50: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 51: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 52: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 53: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 54: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 55: OncoDNA: Product Portfolio
Figure 56: QIAGEN N.V.: Product Portfolio
Figure 57: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 58: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 59: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 60: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
LIST OF TABLES
Table 1: Europe Gene Fusion Testing Market, Impact Analysis
Table 2: Key Questions Answered in the Report
Table 3: Advantages of Gene Fusion Testing
Table 4: Limitations of Gene Fusion Testing
Table 5: NTRK Gene Fusion in Different Types of Cancer
Table 6: Different Types of Gene Fusion
Table 7: Gene Fusion Testing Market: Regulatory Scenario
Table 8: NTRK Test Rate Across Several Europen Countries
Table 1: Europe Gene Fusion Testing Market, Impact Analysis
Table 2: Key Questions Answered in the Report
Table 3: Advantages of Gene Fusion Testing
Table 4: Limitations of Gene Fusion Testing
Table 5: NTRK Gene Fusion in Different Types of Cancer
Table 6: Different Types of Gene Fusion
Table 7: Gene Fusion Testing Market: Regulatory Scenario
Table 8: NTRK Test Rate Across Several Europen Countries
